All John C. Reed articles

News

Johnson & Johnson targets oncology portfolio with $3bn Halda acquisition

2025-11-18T11:02:18Z

Acquisition of the US biotech gives Johnson & Johnson rights to clinical-stage precision treatments for solid tumours.